Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Blood

Volumn 126, Issue 21, 2015, Pages 2362-2365

  Cargo, Catherine A ^a   Rowbotham, Nicola ^a   Evans, Paul A ^a   Barrans, Sharon L ^a   Bowen, David T ^b   Crouch, Simon ^c   Jack, Andrew S ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; DNA METHYLTRANSFERASE 3A; PROTEIN; PROTEIN P53; SRSF2 PROTEIN; TET2 PROTEIN; U2AF1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CYTOGENETICS; CYTOPENIA; DISEASE COURSE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; RISK FACTOR; SURVIVAL RATE;

DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84948771021     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-663237     Document Type: Article

References (15)

1. Parmentier S, Schetelig J, Lorenz K, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012; 97(5): 723-730.
2. Steensma DP Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep. 2012; 7(4): 310-320.
3. Papaemmanuil E, Gerstung M, Malcovati L, et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616-3627, quiz 3699.
4. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2): 241-247.
5. Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011; 117(17): 4552-4560.
6. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488-2498.
7. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477-2487.
8. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12): 1472-1478.
9. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44(6): 642-650.
10. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012; 44(6): 651-658.
11. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1): 9-16.
12. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26(16): 2069-2070.
13. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39(Database issue): D945-D950.
14. Simons A, Sikkema-Raddatz B, de Leeuw N, Konrad NC, Hastings RJ, Schoumans J. Genome-wide arrays in routine diagnostics of hematological malignancies. Hum Mutat. 2012; 33(6): 941-948.
15. Papaemmanuil E, Cazzola M, Boultwood J, et al.; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15): 1384-1395.